Risk of Acute Liver Injury in Agomelatine and Other Antidepressant Users in Four European Countries: A Cohort and Nested Case-Control Study Using Automated Health Data Sources.
Manel PladevallAnton PottegårdTania SchinkJohan ReutforsRosa MorrosBeatriz Poblador-PlouAntje TimmerJoan FornsMaja HellfritzschTammo ReindersDavid HäggMaria Giner-SorianoAlexandra Prados-TorresMiguel Cainzos-AchiricaJesper HallasLena BrandtJordi CortésJaume AguadoGabriel PerlemuterBruno FalissardJordi CastellsaguéEmmanuelle JacquotNicolas DeltourSusana Perez-GutthannPublished in: CNS drugs (2020)
In this study, using citalopram as a comparator, agomelatine was not associated with an increased risk of ALI hospitalisation. The results for agomelatine should be interpreted in the context of the European risk minimisation measures in place. Those measures may have induced selective prescribing and could explain the lower risk of ALI for agomelatine when compared with citalopram. Most other antidepressants evaluated had ORs suggesting a lower risk than citalopram, but additional studies are required to confirm or refute these results.
Keyphrases
- case control
- drug induced
- liver injury
- major depressive disorder
- healthcare
- public health
- primary care
- liver failure
- machine learning
- adverse drug
- drinking water
- electronic health record
- emergency department
- diabetic rats
- respiratory failure
- high throughput
- risk assessment
- health information
- extracorporeal membrane oxygenation
- human health
- stress induced